TransMedics Group (NASDAQ:TMDX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

TransMedics Group (NASDAQ:TMDX) had its price objective hoisted by analysts at Needham & Company LLC from $148.00 to $166.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target suggests a potential upside of 23.15% from the company’s previous close.

TMDX has been the subject of a number of other research reports. Stifel Nicolaus began coverage on shares of TransMedics Group in a report on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price for the company. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Finally, Piper Sandler decreased their target price on shares of TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a research note on Thursday, October 30th. Seven analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $134.80.

TransMedics Group Stock Down 1.3%

Shares of TMDX opened at $134.80 on Monday. The firm has a 50 day simple moving average of $125.94 and a two-hundred day simple moving average of $123.02. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. TransMedics Group has a one year low of $55.00 and a one year high of $156.00. The company has a market cap of $4.61 billion, a P/E ratio of 54.57 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. During the same quarter in the previous year, the firm earned $0.12 EPS. TransMedics Group’s revenue was up 32.2% on a year-over-year basis. Research analysts forecast that TransMedics Group will post 1 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the sale, the insider directly owned 13,955 shares of the company’s stock, valued at $2,026,545.10. The trade was a 17.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David Weill sold 5,000 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the transaction, the director directly owned 12,134 shares of the company’s stock, valued at $1,682,257.76. The trade was a 29.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 13,062 shares of company stock valued at $1,797,634 in the last quarter. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TMDX. Opal Wealth Advisors LLC bought a new stake in TransMedics Group in the second quarter valued at approximately $26,000. Whittier Trust Co. of Nevada Inc. lifted its position in shares of TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares during the period. Salomon & Ludwin LLC acquired a new position in shares of TransMedics Group in the 3rd quarter worth approximately $28,000. Harvest Fund Management Co. Ltd bought a new stake in shares of TransMedics Group in the 3rd quarter valued at $29,000. Finally, Smartleaf Asset Management LLC increased its position in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after buying an additional 135 shares during the period. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.